Chapter 14Strategic Resources & Consequences Report: Case No. 3—Pharmaceutics and Biotech
As in the preceding case study of insurance companies, practically everyone is a customer of drug or biotech companies. Few, though, are satisfied customers. Many complain about exorbitant drug prices, and the socially conscious question the justification for extended patent protection of essential drugs, particularly in Third World countries. If that's not ...
Get The End of Accounting and the Path Forward for Investors and Managers now with the O’Reilly learning platform.
O’Reilly members experience books, live events, courses curated by job role, and more from O’Reilly and nearly 200 top publishers.